World Investment Advisors Raises Position in United Therapeutics Corporation (NASDAQ:UTHR)

World Investment Advisors boosted its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 79.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,328 shares of the biotechnology company's stock after purchasing an additional 1,029 shares during the period. World Investment Advisors' holdings in United Therapeutics were worth $718,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of UTHR. Dunhill Financial LLC raised its holdings in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the period. Sound Income Strategies LLC bought a new stake in United Therapeutics during the 1st quarter valued at $49,000. State of Wyoming bought a new stake in United Therapeutics during the 4th quarter valued at $62,000. Millstone Evans Group LLC bought a new stake in United Therapeutics during the 4th quarter valued at $67,000. Finally, Curat Global LLC bought a new stake in United Therapeutics during the 1st quarter valued at $63,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In related news, Director Richard Giltner sold 3,036 shares of the stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the transaction, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Raymond Dwek sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the transaction, the director directly owned 1,750 shares of the company's stock, valued at $499,747.50. This represents a 63.16% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 76,681 shares of company stock valued at $22,813,739 in the last quarter. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

UTHR traded down $0.40 during trading on Thursday, reaching $300.16. The stock had a trading volume of 498,724 shares, compared to its average volume of 446,148. The stock has a market cap of $13.54 billion, a PE ratio of 11.98, a PEG ratio of 6.58 and a beta of 0.53. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The business has a 50-day moving average of $301.03 and a 200-day moving average of $320.77.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same quarter in the prior year, the firm earned $6.17 earnings per share. The firm's revenue was up 17.2% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on UTHR shares. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Cantor Fitzgerald began coverage on shares of United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target on the stock. Bank of America decreased their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $383.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.